These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17300590)

  • 1. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
    Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):151-2. PubMed ID: 17300590
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA; Stein PP; Thornberry NA; Wagner JA
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Biftu T; Feng D; Qian X; Liang GB; Kieczykowski G; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Scapin G; Patel S; Gao YD; Singh S; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jan; 17(1):49-52. PubMed ID: 17055272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I; Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
    Marino MT
    Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028
    [No Abstract]   [Full Text] [Related]  

  • 8. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Chen P; Caldwell CG; Mathvink RJ; Leiting B; Marsilio F; Patel RA; Wu JK; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5853-7. PubMed ID: 17869513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
    Epstein BJ
    Curr Opin Investig Drugs; 2007 Apr; 8(4):331-7. PubMed ID: 17458184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-431 (Merck).
    Deacon CF
    Curr Opin Investig Drugs; 2005 Apr; 6(4):419-26. PubMed ID: 15898349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements.
    Nordhoff S; Bulat S; Cerezo-Gálvez S; Hill O; Hoffmann-Enger B; López-Canet M; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6340-5. PubMed ID: 19833514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
    Drucker DJ
    Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract]   [Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
    Rosenstock J; Zinman B
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):98-107. PubMed ID: 17940427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Weber AE
    J Med Chem; 2004 Aug; 47(17):4135-41. PubMed ID: 15293982
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M; Yu DM; O'Connor S; Gorrell MD
    Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliptins: a new class of oral hypoglycaemic agent.
    Chahal H; Chowdhury TA
    QJM; 2007 Nov; 100(11):671-7. PubMed ID: 17881415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies: mimetics versus protease inhibitors.
    Brubaker PL
    Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.